Mus vs Qatar: HIV-positive TB patients on ART (antiretroviral therapy)
Mus
100.0%
in 2024
Qatar
100.0%
in 2024
Mus rank
1st
Qatar rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Mus
- Qatar
How they compare
Mus currently reports 100.0% against 100.0% in Qatar, a difference of 0.0%.
Across all 10 years both countries report, Qatar has been ahead every year.
Mus ranks 1st and Qatar ranks 1st of 2 regions.
Qatar has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Mus | Qatar | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 68.0% | 100.0% | 32.0% | Qatar |
| 2010s | 96.7% | 100.0% | 3.3% | Qatar |
| 2020s | 100.0% | 100.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Mus or Qatar?
- Mus, at 100.0% against 100.0% in Qatar as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Mus and Qatar?
- 0.0%, with Mus ahead.
- How many years of comparable data are there for Mus and Qatar?
- 10 years are reported by both, from 2007 to 2024.
- How do Mus and Qatar rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Mus ranks 1st and Qatar ranks 1st of 2 regions.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.